Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells
about
Targeting cellular metabolism to improve cancer therapeuticsPotential role of tumor necrosis factor-α in downregulating sex hormone-binding globulinMonosaccharide-induced lipogenesis regulates the human hepatic sex hormone-binding globulin geneTargeting metabolism in breast cancer: How far we can go?The diverse role of the PPARγ coactivator 1 family of transcriptional coactivators in cancerLipid biology of breast cancerThe role of HGF/c-MET signaling pathway in lymphomaEfficacy of a non-hypercalcemic vitamin-D2 derived anti-cancer agent (MT19c) and inhibition of fatty acid synthesis in an ovarian cancer xenograft modelBlockade of fatty acid synthase triggers significant apoptosis in mantle cell lymphomaLipid metabolism emerges as a promising target for malignant glioma therapy.Genome-wide changes accompanying knockdown of fatty acid synthase in breast cancer.Pathogenesis of ovarian cancer: clues from selected overexpressed genes.The mTOR inhibitor rapamycin synergizes with a fatty acid synthase inhibitor to induce cytotoxicity in ER/HER2-positive breast cancer cellsSerous tubal intraepithelial carcinoma upregulates markers associated with high-grade serous carcinomas including Rsf-1 (HBXAP), cyclin E and fatty acid synthaseThe nonsteroidal anti-inflammatory drug tolfenamic acid inhibits BT474 and SKBR3 breast cancer cell and tumor growth by repressing erbB2 expression.HO-3867, a synthetic compound, inhibits the migration and invasion of ovarian carcinoma cells through downregulation of fatty acid synthase and focal adhesion kinase.Association of lipid metabolism with ovarian cancerFatty acid synthase inhibition by amentoflavone suppresses HER2/neu (erbB2) oncogene in SKBR3 human breast cancer cells.Inhibitory effect of LXR activation on cell proliferation and cell cycle progression through lipogenic activity.De novo lipogenesis maintains vascular homeostasis through endothelial nitric-oxide synthase (eNOS) palmitoylation.Roles of the active site water, histidine 303, and phenylalanine 396 in the catalytic mechanism of the elongation condensing enzyme of Streptococcus pneumoniae.Silencing expression of UO-44 (CUZD1) using small interfering RNA sensitizes human ovarian cancer cells to cisplatin in vitro.Expressions of fatty acid synthase and HER2 are correlated with poor prognosis of ovarian cancer.Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells.Up-regulation of acetyl-CoA carboxylase alpha and fatty acid synthase by human epidermal growth factor receptor 2 at the translational level in breast cancer cells.Cerulenin blockade of fatty acid synthase reverses hepatic steatosis in ob/ob mice.Plasma metabolite profiling and chemometric analyses of lung cancer along with three controls through gas chromatography-mass spectrometry.Signalling mechanisms regulating phenotypic changes in breast cancer cells.Fatty acid synthase as a potential therapeutic target in cancer.Metformin: multi-faceted protection against cancer.ACLY and ACC1 Regulate Hypoxia-Induced Apoptosis by Modulating ETV4 via α-ketoglutarate.Multiplexing siRNAs to compress RNAi-based screen size in human cells.A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines.Interfering with cancer: a brief outline of advances in RNA interference in oncology.Palmitate-induced ER stress increases trastuzumab sensitivity in HER2/neu-positive breast cancer cellsElevated expression of DecR1 impairs ErbB2/Neu-induced mammary tumor development.The potential utility of acetyltanshinone IIA in the treatment of HER2-overexpressed breast cancer: Induction of cancer cell death by targeting apoptotic and metabolic signaling pathwaysPotential applications of RNA interference technology in the treatment of cancer.ras-Induced up-regulation of CTP:phosphocholine cytidylyltransferase α contributes to malignant transformation of intestinal epithelial cells.Potential use of humanized antibodies in the treatment of breast cancer.
P2860
Q24596727-6FA66724-FEA0-43CC-A4FD-BFB0919DFB34Q24602925-DDBD9EA4-3947-44B8-BCBE-9C01481F2D34Q24681894-10CF792B-F6DD-47D5-9E4B-B02F7C2B44AFQ26767022-F91E1D91-274F-448A-A902-717998238182Q26997789-4A66091B-30BF-4B55-8361-BED000D41E44Q27013858-4404951D-DD0D-4994-8516-EDEEB8CE816AQ28069836-B61FD5B7-A8FE-40DA-8A31-D9B721953684Q28482093-900E33DF-64D9-44B3-B87D-30F07350C595Q28730808-264CB9C0-65F4-4551-ACC9-674E96F45D6BQ30684049-5D3462E0-40E1-4643-B9F5-510E669FF2E6Q33287507-7453BA79-6B5F-426A-8FDE-6DE8D68183C2Q33651139-05ADEAD6-20CB-4C37-8AED-A4A97B4FE8C8Q33670472-DB9DCCE6-9481-4303-903F-FB534F6B0F4FQ33888942-6A8B2BF4-883C-439F-8014-C63EE81E6A70Q34127212-CBDC7E2A-A2BF-483A-8331-53F14B003371Q34139276-1E097D02-3C6A-4A92-8EAA-CF167494A3AEQ34171997-E7F5BBEA-F666-46B6-8941-636836D845FBQ34286341-94505FBC-5FFA-45DE-B911-6E4292CDAAC9Q34287799-4A2DC3FF-196C-49A9-84A6-F5FED40C45A8Q34509518-67DAA87E-F3F0-43A3-991C-26201E127FFFQ34514386-EE97A367-436E-40B8-9FB3-A8E96BBCF8F6Q34550420-720C92B2-4757-440C-A394-5429613A5C41Q34587948-034DBB48-B0FD-4E92-B48C-6AC98FF6C746Q34613543-113F2FCA-C3E2-4EAA-A6AB-57C73EAF3C7AQ34650973-B2467816-A00B-4053-ADA1-443849E6D7F3Q35006116-3B22FD92-4BD8-4A69-925B-3A7005278905Q35119518-1307BA42-1413-4C48-9BF3-77261B5B5789Q35207250-0A8B7CF4-87F6-44C8-8660-243BC11513A6Q35401716-49AF739D-05BE-4836-89FA-7261C0E98CCFQ35764409-8760DAE0-A971-4DBA-A55C-AB72323834C3Q35801707-DEBE8E9F-418F-4A66-BC81-B297376E353AQ35829326-6A56D1EC-A633-4E99-9C8C-A6A0D2206B11Q35889665-B1F2979D-19E3-4C20-961F-1E0A2717CFA5Q35997754-D4757F45-8408-4C7E-933D-13C970DEA94AQ36087653-78A44CE4-796E-47D9-959D-5E0901E8A6B5Q36177509-130582CA-7EC7-4E88-BCF6-FB858C3A75BCQ36355817-1C0547F2-5E2D-4BB6-AFF2-EAF524329C75Q36429400-6AA459EF-DB48-41A4-B870-5D2BD5C82F23Q36508749-F9AFEB66-9CFA-4CCB-B44A-79426323192CQ36532110-CA89256A-D2B1-4375-B319-83105025FD0C
P2860
Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells
description
2004 nî lūn-bûn
@nan
2004 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
name
Inhibition of fatty acid synth ...... overexpression in cancer cells
@ast
Inhibition of fatty acid synth ...... overexpression in cancer cells
@en
Inhibition of fatty acid synth ...... overexpression in cancer cells
@nl
type
label
Inhibition of fatty acid synth ...... overexpression in cancer cells
@ast
Inhibition of fatty acid synth ...... overexpression in cancer cells
@en
Inhibition of fatty acid synth ...... overexpression in cancer cells
@nl
prefLabel
Inhibition of fatty acid synth ...... overexpression in cancer cells
@ast
Inhibition of fatty acid synth ...... overexpression in cancer cells
@en
Inhibition of fatty acid synth ...... overexpression in cancer cells
@nl
P2093
P2860
P3181
P356
P1476
Inhibition of fatty acid synth ...... overexpression in cancer cells
@en
P2093
Bharvi P Oza
Inderjit Mehmi
Luciano Vellon
Santiago Ropero
P2860
P304
10715-10720
P3181
P356
10.1073/PNAS.0403390101
P407
P577
2004-07-02T00:00:00Z